Market Access Impact: Cancer Pain (EU5) 2017

Maximum Purchase:
1 unit
Publication Date:
September 2017
Adding to cart… The item has been added

Market barriers may not be the only reason doctors don’t prescribe your brand

Market barriers only affect 12% of cancer pain prescriptions in the EU5 countries. Most brands gain market share because of them, but for some brands, perception may be an even bigger problem. And over 10% of doctors  either wouldn’t prescribe these brands, or simply haven’t heard of them at all.

Find out how doctors see your brand, and whether market barriers are dragging your market share down, in Market Access Impact: Cancer Pain (EU5).

Based on a survey of 150 medical oncologists, the report covers 7 major therapies from Kyowa Kirin, Teva, Takeda, and Mundipharma/Napp. Handy graphs and charts show you how 7 barriers affect your market share, revealing which competitors you gain share from, and lose it to.

Not your market? Click here to see the US Edition.

Request sample pages

Top Takeaways

  • Most brands gain. While every brand wins and loses share because of barriers, 5 of the 7 surveyed brands see a net gain, albeit very small for some brands.
  • No one barrier is to blame. Most of the 7 barriers covered in the report affect the same amount of prescriptions.
  • Barrier impact is small. Over 45-65% of surveyed doctors experience only one barrier with any given brand, but for some brands that climbs to 3 barriers.
  • Some brands are hit harder by certain barriers. Learn which brand doctors have the most trouble reimbursing, which three products lose out due to patient type recommendations, and more.
  • Do the brands have a perception problem? Up to 30% of doctors either wouldn’t consider prescribing these brands, or haven’t heard of them at all.

Insight into 7 Major Cancer Pain Treatments

  • Abstral (fentanyl sublingual; Kyowa Kirin)
  • Actiq (fentanyl transmucosal; Teva)
  • Effentora (fentanyl buccal; Teva)
  • Instanyl (fentanyl intranasal; Takeda)
  • Oxycontin (oxycodone CII; Mundipharma/Napp)
  • OxyNorm (oxycodone IR; Mundipharma/Napp)
  • PecFent (fentanyl intranasal; Kyowa Kirin)

Exploring Important Market Access Issues

Market Access Impact: Cancer Pain (EU5) explores key issues affecting drug manufacturers. You’ll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest impact?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don’t, but would consider it?
  • Why don’t doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 150 medical oncologists—30 from each EU5 country (France, Italy, Germany, Spain, UK)chosen from the largest community of validated physicians in the world.

All respondents have:

  • Been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients with cancer pain in total in the last month

We conducted the survey between September 1-12, 2017.

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

  • FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
  • FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at